NASDAQ:IDXG

Interpace Biosciences (IDXG) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.45
$1.54
50-Day Range
$4.75
$10.40
52-Week Range
$2.57
$10.42
Volume
4,751 shs
Average Volume
5,226 shs
Market Capitalization
$6.41 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDXG stock logo

About Interpace Biosciences Stock (NASDAQ:IDXG)

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

IDXG Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
PDI: 14% Yield, But Risks Are Rising (Rating Downgrade)
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
PDI: Lag Likely To Continue
PDI: Pain Could Be On The Horizon
PDI And PTY: Unwelcome ROC, Buyer Beware
PTY And PDI: Abysmal Setups
See More Headlines
Receive IDXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Interpace Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/29/2023
Today
4/24/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:IDXG
CUSIP
69329V10
Employees
152
Year Founded
N/A

Profitability

Net Income
$800,000.00
Pretax Margin
2.81%

Debt

Sales & Book Value

Annual Sales
$40.21 million
Cash Flow
$0.64 per share
Book Value
($14.16) per share

Miscellaneous

Free Float
4,084,000
Market Cap
$6.41 million
Optionable
Not Optionable
Beta
0.64
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Thomas W. Burnell Ph.D. (Age 58)
    Pres, CEO & Director
    Comp: $425k
  • Mr. Thomas John Freeburg Ph.D. (Age 52)
    Chief Accounting Officer, CFO, Treasurer & Sec.
  • Dr. Sydney D. Finkelstein
    Chief Scientific Officer
  • Dr. Alidad Mireskandari M.B.A.
    Ph.D., Chief Devel. Officer
  • Mr. Patrick Kane
    VP & Corp. Controller

IDXG Stock Analysis - Frequently Asked Questions

When is Interpace Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our IDXG earnings forecast
.

How were Interpace Biosciences' earnings last quarter?

Interpace Biosciences, Inc. (NASDAQ:IDXG) released its earnings results on Wednesday, March, 29th. The business services provider reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.26. The business services provider had revenue of $8.33 million for the quarter. Interpace Biosciences had a negative trailing twelve-month return on equity of 1.79% and a net margin of 1.99%.

What other stocks do shareholders of Interpace Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

This page (NASDAQ:IDXG) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners